Kabakov A V, Kazakov O V, Poveshchenko A F, Cherkas V N, Kononchuk V V, Kalinina T S, Bodrova N R
Research Institute of Clinical and Experimental Lymphology - Branch of Federal Research Center Institute of Cytology and Genetics, Siberian Branch of the Russian Academy of Sciences, Novosibirsk, Russia.
Bull Exp Biol Med. 2025 Jan;178(3):360-362. doi: 10.1007/s10517-025-06336-8. Epub 2025 Feb 13.
The study examined the quantitative variations in the levels of pro-oncogenic miRNAs (miRNA-21, miRNA-27a, and miRNA-221) and tumor-suppressive miRNA-429 in blood serum and lymph of female Wistar rats with breast cancer after photodynamic therapy and controls (without treatment). The levels of pro-oncogenic miRNA-21 and miRNA-221 in the blood serum and lymph increased in the control group. Photodynamic therapy significantly reduced the levels of these miRNAs, suggesting the effectiveness of the treatment. The levels of pro-oncogenic miRNA-27a in the blood serum and lymph of both groups were multidirectional. The levels of tumor-suppressing miRNA-429 decreased significantly in the control group and remained low after photodynamic therapy. Therefore, miRNA-21 and miRNA-221 in the blood serum and lymph can be used as markers of the effectiveness of photodynamic therapy.
该研究检测了光动力治疗后乳腺癌雌性Wistar大鼠血清和淋巴中促癌miRNA（miRNA-21、miRNA-27a和miRNA-221）以及抑癌miRNA-429水平的定量变化，并与对照组（未治疗）进行了比较。对照组血清和淋巴中促癌miRNA-21和miRNA-221水平升高。光动力治疗显著降低了这些miRNA的水平，表明该治疗方法有效。两组血清和淋巴中促癌miRNA-27a的水平变化方向不一。对照组中抑癌miRNA-429水平显著降低，光动力治疗后仍维持在低水平。因此，血清和淋巴中的miRNA-21和miRNA-221可作为光动力治疗效果的标志物。
